B+
Bull case
20%
Probability
Target price
$3.60
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CVRX
CVRxFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+45.6
Score
AI commentary
News tone is mixed-to-negative: Q2 growth, margin, Humana coverage, and center expansion were constructive, but the guidance cut and sales-execution disclosures dominate the post-print narrative [#SEC-8K-2026-08-06]. The 2026-08-07 anchor price was $2.39, but a reliable pre/post earnings price comparison was unavailable. Consensus surprise data, analyst revisions, and target changes were also unavailable, and low coverage limits confidence. Social, options, short-interest, and employee-sentiment data were not available in the packet.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-06catalystQ3 execution against reset guidanceHigh impact
Q2 revenue of $15.7 million was within the prior $15.1-$16.1 million guide, with 87% gross margin and U.S. revenue up 21%; the next test is delivery against the reset Q3 revenue range of $13.5-$14.5 million [#SEC-8K-2026-08-06].
2027-08-08eventCommercial and payer execution recoveryHigh impact
Management cited fewer sales territories, lower sales-force productivity, and a prolonged large-payer challenge as the reasons for the outlook reduction. Evidence of territory productivity improvement or payer resolution would support recovery, while Humana coverage and CPT progress provide a partial offset [#SEC-8K-2026-08-06].
2027-08-08catalystBENEFIT-HF enrollment and reimbursement expansionHigh impact
The BENEFIT-HF trial and broader reimbursement strategy remain the principal longer-term expansion paths. Humana coverage, Category I CPT codes, and CMS Category B IDE coverage are constructive, but trial progress remains early and no outcomes date is disclosed [#SEC-8K-2026-08-06] [#SEC-8K-2026-05-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology